| Literature DB >> 1167630 |
Abstract
The minimum exposure to estrogen required to cause estrogen-withdrawal migraine has been studied by giving long-acting estradiol valerate to four women and short-acting estradiol benzoate to two women. It was found that several days of exposure to high estrogen levels were needed to cause migraine on estrogen withdrawal. Oral administration of estrogen supplements in the form of estradiol valerate or as conjugated equine estrogens during the premenstrual phase in four women did not significantly affect plasma levels of estradiol, nor was it effective in preventing menstrual migraine.Entities:
Mesh:
Substances:
Year: 1975 PMID: 1167630 DOI: 10.1212/wnl.25.3.239
Source DB: PubMed Journal: Neurology ISSN: 0028-3878 Impact factor: 9.910